NCT03149991View on ClinicalTrials.gov

A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

PHASE4CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

September 14, 2017

Primary Completion Date

March 31, 2019

Study Completion Date

June 15, 2019

Conditions
Depression
Interventions
DRUG

Brexpiprazole

Administration of up to 3mg brexpiprazole

DRUG

Ketamine

administration 6 times over two weeks of inhaled ketamine

DRUG

Placebo

Administration of placebo which matches brexpiprazole in size and number of tablets per dose

Trial Locations (6)

10467

Montefiore Medical Center, The Bronx

10562

Nathan Kline Institute for Psychiatric Research, Orangeburg

60612

Rush University Medical Center, Chicago

92845

Collaborative Neuroscience Network, LLC., Garden Grove

94607

Pacific Research Partners, LLC, Oakland

02114

Massachusetts General Hospital, Depression Clinical and Research Program, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT03149991 - A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD) | Biotech Hunter | Biotech Hunter